Skip to main navigation Skip to search Skip to main content

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

  • Sylvia Adams
  • , Megan Othus
  • , Sandip Pravin Patel
  • , Kathy D. Miller
  • , Rashmi Chugh
  • , Scott M. Schuetze
  • , Mary D. Chamberlin
  • , Barbara J. Haley
  • , Anna Maria V. Storniolo
  • , Mridula P. Reddy
  • , Scott A. Anderson
  • , Collin T. Zimmerman
  • , Anne P. O’Dea
  • , Hamid R. Mirshahidi
  • , Jordi Rodon Ahnert
  • , Frank J. Brescia
  • , Olwen Hahn
  • , Jane M. Raymond
  • , David D. Biggs
  • , Roisin M. Connolly
  • Elad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)271-278
Number of pages8
JournalClinical Cancer Research
Volume28
Issue number2
DOIs
StatePublished - Jan 15 2022

ASJC Scopus Subject Areas

  • General Medicine

Keywords

  • Prospective Studies
  • Humans
  • Middle Aged
  • Aged, 80 and over
  • Ipilimumab/therapeutic use
  • Adult
  • Female
  • Aged
  • Nivolumab/therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Breast Neoplasms/drug therapy

Cite this